[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013029016A2 - métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar - Google Patents

métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar

Info

Publication number
BR112013029016A2
BR112013029016A2 BR112013029016A BR112013029016A BR112013029016A2 BR 112013029016 A2 BR112013029016 A2 BR 112013029016A2 BR 112013029016 A BR112013029016 A BR 112013029016A BR 112013029016 A BR112013029016 A BR 112013029016A BR 112013029016 A2 BR112013029016 A2 BR 112013029016A2
Authority
BR
Brazil
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
modulation methods
microwave modulation
Prior art date
Application number
BR112013029016A
Other languages
English (en)
Inventor
Andrew Baker
Margaret Maclean
Nicholas Morrell
Original Assignee
Cambridge Entpr Ltd
Univ Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd, Univ Glasgow filed Critical Cambridge Entpr Ltd
Publication of BR112013029016A2 publication Critical patent/BR112013029016A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

abstract not avaible
BR112013029016A 2011-05-09 2012-05-09 métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar BR112013029016A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161484091P 2011-05-09 2011-05-09
US201261605376P 2012-03-01 2012-03-01
PCT/GB2012/051018 WO2012153135A1 (en) 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
BR112013029016A2 true BR112013029016A2 (pt) 2017-01-17

Family

ID=46178572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029016A BR112013029016A2 (pt) 2011-05-09 2012-05-09 métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar

Country Status (11)

Country Link
US (1) US9267134B2 (pt)
EP (1) EP2707485B1 (pt)
JP (1) JP6049700B2 (pt)
KR (1) KR20140037868A (pt)
CN (1) CN103814131A (pt)
AU (1) AU2012252165A1 (pt)
BR (1) BR112013029016A2 (pt)
CA (1) CA2835568A1 (pt)
CO (1) CO6870004A2 (pt)
SG (1) SG194901A1 (pt)
WO (1) WO2012153135A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
MX364814B (es) 2013-03-15 2019-05-08 Miragen Therapeutics Inc Nucleosidos biciclicos unidos en puente.
EP3077509A1 (en) * 2013-12-02 2016-10-12 The University Court Of The University Of Glasgow Materials and methods for treatment of pulmonary arterial hypertension
AU2015296037B2 (en) * 2014-08-01 2021-04-29 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
BR112017014914B1 (pt) 2015-01-13 2023-11-14 Vivus, Inc Uso de uma combinação de tacrolimus e um segundo agente ativo eficaz no tratamento ou prevenção da hipertensão pulmonar
US10874688B2 (en) * 2016-10-31 2020-12-29 Gifu University Double-stranded nucleic acid molecule and use thereof
AU2020399633A1 (en) * 2019-12-09 2022-07-07 Empirico Inc. Oligonucleotides for treatment of Angiopoietin like 4 (ANGPTL4) related diseases
JP2024504679A (ja) * 2021-01-18 2024-02-01 リジェン イノファーム インコーポレイテッド ｍｉＲ１４５阻害剤を有効成分として含む心筋梗塞の治療用組成物
CN113332306A (zh) * 2021-04-28 2021-09-03 武汉华纪元生物技术开发有限公司 用于治疗肺动脉高血压的microRNA-30a抑制剂及其应用
GB202215974D0 (en) * 2022-10-28 2022-12-14 Imperial College Innovations Ltd Microrna panels for pulmonary hypertension

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
AU7404994A (en) 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
ES2171945T3 (es) 1996-05-31 2002-09-16 C & C Res Lab Derivados aromaticos de amidina que sirven de inhibidores selectivos de la trombina.
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
SK17432000A3 (sk) 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
CA2345641A1 (en) 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
CA2557480A1 (en) 2004-02-26 2005-09-09 V-Kardia Pty Ltd Isolating cardiac circulation
US20060148742A1 (en) 2004-02-26 2006-07-06 Kaye David M Polynucleotide delivery to cardiac tissue
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
EP2671949A1 (en) 2005-12-12 2013-12-11 University Of North Carolina At Chapel Hill Micro-RNA miR-145 that regulate muscle cell proliferation and differentiation
WO2009121031A1 (en) 2008-03-27 2009-10-01 Vascular Biosciences, Inc. Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US8735568B2 (en) 2009-03-09 2014-05-27 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
CN101843632B (zh) * 2009-03-24 2012-07-04 复旦大学附属华山医院 miR-145在制备治疗炎症药物中的应用
EP2440566A4 (en) * 2009-06-08 2013-10-16 Miragen Therapeutics CHEMICAL MODIFICATION RULES FOR INHIBITORS AND MIMETICS OF MIRIK
EP2513307A4 (en) * 2009-12-15 2014-02-26 Univ Texas MICRO-RNA REGULATION IN ISCHEMIA AND ISCHEMIA REPERFUSION INJURIES
CN102382824A (zh) * 2010-09-01 2012-03-21 中国科学院上海药物研究所 人miR-145反义核酸及其应用

Also Published As

Publication number Publication date
AU2012252165A1 (en) 2013-03-21
EP2707485B1 (en) 2016-12-14
SG194901A1 (en) 2013-12-30
JP6049700B2 (ja) 2016-12-21
WO2012153135A1 (en) 2012-11-15
US20140163086A1 (en) 2014-06-12
CA2835568A1 (en) 2012-11-15
KR20140037868A (ko) 2014-03-27
CO6870004A2 (es) 2014-02-20
CN103814131A (zh) 2014-05-21
US9267134B2 (en) 2016-02-23
JP2014516027A (ja) 2014-07-07
EP2707485A1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
BR112013029016A2 (pt) métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar
CYD2019001I1 (el) Διαμορφωση της εκφρασης τρανσθυρετινης
BR112013028315A2 (pt) propantes curados e revestidos
LT3354747T (lt) Neinvazinis naviko metilomos nustatymas iš plazmos
EP2768514A4 (en) LOCALIZED MODULATION OF TISSUES AND CELLS TO IMPROVE THERAPEUTIC EFFECTS INCLUDING RENAL RECURRING
DK3586644T3 (da) Fremstilling af bælgfrugtproteinprodukter med reduceret astringens
DK2591099T3 (da) Kimære koagulationsfaktorer
EP2872128A4 (en) NICOTINAMIDE RIBOSIDE TO TREAT HEARING LOSS
EP2822647A4 (en) SELECTIVE MODULATION OF RENAL NERVES
BR112013024211A2 (pt) tratamento de tumores sólidos
PL2871944T3 (pl) Sposób perfuzji organu
EP2864479A4 (en) MODULATION OF THE UBE3A ATS EXPRESSION
EP2879682A4 (en) TREATMENT OF PULMONARY ARTERIAL HIGH PRESSURE WITH MESENCHYMAL STEM CELLS
BR112013025755A2 (pt) aparelho de guincho
BR112014001219A2 (pt) perfume
EP2877589A4 (en) GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
EP2879684A4 (en) TREATMENT OF LUNGSARTERIAL HIGH PRESSURE WITH PROSTACYCLINE-TREATED ENDOTHEL PREORDER CELLS
EP2776564A4 (en) MODULATION OF TMPRSS6.EXPRESSION
IL246269B (en) Compositions and methods for treating fatty tissue buildup
FI20116335A (fi) Perhappojen tehokkuuden parantaminen
EP2600896A4 (en) Treating breast cancer with anti-il-19 antibody
HK1204964A1 (en) Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote xa
BR112013029459A2 (pt) turbina, método de operar uma turbina e veículo
BR112013023144A2 (pt) método de tratamento de couro cabeludo

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]